2019-nCoV Antigen Test was approved by CFDA
Recently, the new coronavirus (2019-nCoV) antigen (Colloidal gold) developed by Xiamen Wiz Biotech Co., Ltd. has been approved by CFDA.
The approved product detects COVID-19 infection through nasopharyngeal swabs or nasal swabs. The test results can be obtained within 15 minutes. The testing process is safe, convenient and fast, which greatly improves the efficiency of novel coronavirus detection and better meets the needs of home testing, disease prevention and control.
Who can do the test?
① Personnel with the need for autonomous antigen detection.
② Personnel in crowded places (large enterprises, construction sites, universities, etc.).
③ The elderly at home and in nursing homes.
As an enterprise that has been deeply engaged in POCT for nine years, in the face of the optimization and adjustment of epidemic prevention policies, nucleic acid testing is speeding up its exit, and antigen testing is an important supplement to enter the market quickly. In order to meet the end users' demand for test kit reserve, Wiz Biotech will follow up and optimize the production plan in a comprehensive, rapid and accurate way, and actively expand production to improve production capacity and ensure market supply. In this way, the needs of the self-tested population can be guaranteed to the greatest extent, and the lives and health of the public can be protected.
